Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 299, Issue 2, 2010, Pages

  Pamuk, Omer Nuri ^a,b   Lapchak, Peter H ^a   Rani, Poonam ^a   Pine, Polly ^c   Dalle Lucca, Jurandir J ^d   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TRAKYA UNIVERSITY   (Turkey)

^c RIGEL PHARMACEUTICALS INC   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

R788; Syk; Syk inhibition

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 788; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; C57BL 6 MOUSE; CELL INFILTRATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME INHIBITION; FEEDING; INFLAMMATION; ISCHEMIA; LUNG INJURY; MESENTERY; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; POLYMORPHONUCLEAR CELL; PREVENTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; T LYMPHOCYTE; TISSUE INJURY;

ANIMALS; COMPLEMENT C3; ENZYME ACTIVATION; ENZYME INHIBITORS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTESTINES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; OXAZINES; PROTEIN-TYROSINE KINASES; PULMONARY CIRCULATION; PYRIDINES; RECEPTORS, CELL SURFACE; REPERFUSION INJURY; SPLANCHNIC CIRCULATION;

EID: 77955622884     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00198.2010     Document Type: Article

References (34)

1. Anderson J, Fleming SD, Rehrig S, Tsokos GC, Basta M, Shea-Donohue T. Intravenous immunoglobulin attenuates mesenteric ischemia-reperfusion injury. Clin Immunol 114: 137-146, 2005. (Pubitemid 40082379)
2. Asman B, Gustafsson A, Bergstrom K. Priming of neutrophils with tumor necrosis factor-alpha measured as Fcgamma receptor-mediated respiratory burst correlates with increased complement receptor 3 membrane density. Int J Clin Lab Res 26: 236-239, 1996. (Pubitemid 27052587)
3. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 58: 1433-1444, 2008.
4. Berton G, Mocsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol 26: 209-213, 2005.
5. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319: 998-1008, 2006.
6. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, Firestein GS. A novel spleen tyrosine inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 317: 571-578, 2006.
7. Chen J, Crispin JC, Tedder TF, Lucca JD, Tsokos GC. B cells contribute to ischemia/reperfusion-mediated tissue injury. J Autoimmun 32: 195-200, 2009.
8. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. Arch Surg 101: 478-483, 1970.
9. Conner WC, Gallagher CM, Miner TJ, Tavaf-Mutamen KM, Wolcott H, Shea-Donohue T. Neutrophil priming state predicts capillary leak after gut ischemia in rats. J Surg Res 84: 24-30, 1999. (Pubitemid 29391595)
10. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawforf JM, Ferrara JL. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 8: 3230-3239, 1996. (Pubitemid 26357409)
11. Deng GM, Liu L, Bahjat R, Pine PR, Tsokos GC. Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice. Arthritis Rheum (March 10, 2010). doi:10.1002/art.27452.
12. Diepenhorst GMP, van Gulik TM, Hack CE. Complement-mediated ischemia-reperfusion injury. Lesson learned from animal and clinical studies. Ann Surg 249: 889-899, 2009.
13. Edgerton C, Crispin JC, Moratz CM, Bettelli E, Oukka M, Simovic M, Zacharia A, Egan R, Chen J, Dalle Lucca JJ, Juang YT, Tsokos GC. IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clin Immunol 130: 313-321, 2009.
14. Fleming SD, Anderson J, Wilson F, Shea-Donohue T, Tsokos GC. C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusion. Clin Immunol 106: 55-64, 2003. (Pubitemid 36263303)
15. Fleming SD, Shea-Donohue T, Gutheridge JM, Kulik L, Waldschmidt TJ, Gipson MG, Tsokos GC, Holers VM. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 169: 2126-2133, 2002.
16. Fleming SD, Tsokos GC. Complement, natural antibodies, autoantibodies and tissue injury. Autoimmun Rev 5: 89-92, 2006. (Pubitemid 43136464)
17. Ghosh D, Tsokos GC. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity 43: 48-55, 2010.
18. Johnson P, Cross JL. Tyrosine phosphorylation in immune cells: direct and indirect effects on toll-like receptor-induced proinflammatory cytokine production. Crit Rev Immunol 29: 347-367, 2009.
19. Karpel-Massler G, Fleming SD, Kirschfink M, Tsokos GC. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res 115: 247-256, 2003. (Pubitemid 38021915)
20. Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, Nambiar MP, Kyttaris V, Weinstein A, Bahjat R, Pine P, Rus V, Tsokos GC. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 181: 8145-8152, 2008.
21. Kurosaki T, Hikida M. Tyrosine kinase and their substrates in B lymphocytes. Immunol Rev 228: 132-148, 2009.
22. Kyttaris VC, Tsokos GC. Syk kinase as a treatment target for therapy in autoimmune diseases. Clin Immunol 124: 235-237, 2007. (Pubitemid 47260592)
23. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282: C227-C241, 2002. (Pubitemid 34663181)
24. Page TH, Smolinska M, Gillespie J, Urbaniak AM, Foxwell BM. Tyrosine kinases and inflammatory signaling. Curr Mol Med 9: 69-85, 2009.
25. Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin Ther Pat 19: 1361-1376, 2009.
26. Shi T, Moulton VR, Lapchak PH, Deng GM, Lucca JJD, Tsokos GC. Ischemia-mediated aggregation of the actin cytoskeleton is one of the major initial events resulting in ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 296: G339-G347, 2009.
27. Shi Y, Tohyama Y, Kadono T, He J, Miah SM, Hazama R, Tanaka C, Tohyama K, Yamamura H. Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis. Blood 107: 4554-4562, 2006. (Pubitemid 43801385)
28. Tohyama Y, Yamamura H. Complement-mediated phagocytosis - the role of Syk. IUBMB Life 58: 304-308, 2006.
29. Tohyama Y, Yamamura H. Protein tyrosine kinase Syk: a key player in phagocytic cells. J Biochem 145: 267-273, 2009.
30. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E. Treatment of rheumatoid arthritis with a Syk inhibitor. A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58: 3309-3318, 2008.
31. Williams JP, Pechet TTV, Weiser MR, Reid R, Kobzik L, Moore FD, Carroll MC, Hechtman HB. Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol 86: 938-942, 1999. (Pubitemid 29118016)
32. Zhang M, Austen WG Jr, Chiu I, Alicot EM, Hung R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD Jr, Carroll MC. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 101: 3886-3891, 2004.
33. Zhao H, Montalto MC, Pfeiffer KJ, Hao L, Stahl GL. Murine model of gastrointestinal ischemia associated with complement-dependent injury. J Appl Physiol 93: 338-345, 2002. (Pubitemid 34686230)
34. Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, Clemens GR. Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol 221: 268-277, 2007.